Fortress Biotech, Inc. (FBIO): Price and Financial Metrics


Fortress Biotech, Inc. (FBIO): $0.85

-0.04 (-4.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FBIO POWR Grades

  • FBIO scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.41% of US stocks.
  • FBIO's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • FBIO ranks lowest in Quality; there it ranks in the 9th percentile.

FBIO Stock Summary

  • FBIO has a market capitalization of $95,907,257 -- more than approximately merely 18.26% of US stocks.
  • Over the past twelve months, FBIO has reported earnings growth of 184.08%, putting it ahead of 91.47% of US stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for FBIO comes in at -51.17% -- higher than that of merely 9.79% of stocks in our set.
  • Stocks that are quantitatively similar to FBIO, based on their financial statements, market capitalization, and price volatility, are TVTX, TDUP, APM, PXLW, and LXRX.
  • FBIO's SEC filings can be seen here. And to visit FORTRESS BIOTECH INC's official web site, go to www.fortressbiotech.com.

FBIO Valuation Summary

  • In comparison to the median Healthcare stock, FBIO's EV/EBIT ratio is 100.99% lower, now standing at -0.1.
  • FBIO's EV/EBIT ratio has moved up 6 over the prior 136 months.

Below are key valuation metrics over time for FBIO.

Stock Date P/S P/B P/E EV/EBIT
FBIO 2023-01-30 1.3 1.6 -1.1 -0.1
FBIO 2023-01-27 1.3 1.6 -1.1 -0.1
FBIO 2023-01-26 1.2 1.6 -1.1 0.0
FBIO 2023-01-25 1.3 1.6 -1.1 -0.1
FBIO 2023-01-24 1.3 1.7 -1.1 -0.1
FBIO 2023-01-23 1.4 1.7 -1.2 -0.2

FBIO Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 1.75%.
  • Its year over year revenue growth rate is now at 83.27%.
  • Its 2 year net income to common stockholders growth rate is now at -33.36%.
FBIO's revenue has moved up $24,961,000 over the prior 15 months.

The table below shows FBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 77.615 -170.253 -91.192
2022-06-30 82.172 -148.676 -89.462
2022-03-31 81.129 -141.712 -71.641
2021-12-31 68.791 -116.54 -64.703
2021-09-30 64.264 -98.33 -38.433
2021-06-30 52.654 -100.526 -33.199

FBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FBIO has a Quality Grade of D, ranking ahead of 14.81% of graded US stocks.
  • FBIO's asset turnover comes in at 0.147 -- ranking 224th of 682 Pharmaceutical Products stocks.
  • MGNX, MTEX, and MNKKQ are the stocks whose asset turnover ratios are most correlated with FBIO.

The table below shows FBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.147 0.638 -0.159
2021-03-31 0.138 0.668 -0.248
2020-12-31 0.163 0.680 -0.265
2020-12-31 0.163 0.680 -0.265
2020-09-30 0.169 0.677 -0.339
2020-06-30 0.183 0.695 -0.332

FBIO Price Target

For more insight on analysts targets of FBIO, see our FBIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.17 Average Broker Recommendation 1.5 (Moderate Buy)

FBIO Stock Price Chart Interactive Chart >

Price chart for FBIO

FBIO Price/Volume Stats

Current price $0.85 52-week high $2.10
Prev. close $0.88 52-week low $0.48
Day low $0.82 Volume 423,300
Day high $0.88 Avg. volume 505,209
50-day MA $0.75 Dividend yield N/A
200-day MA $0.88 Market Cap 91.07M

Fortress Biotech, Inc. (FBIO) Company Bio


Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company was founded in 2006 and is based in New York, New York.


FBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

FBIO Latest Social Stream


Loading social stream, please wait...

View Full FBIO Social Stream

Latest FBIO News From Around the Web

Below are the latest news stories about FORTRESS BIOTECH INC that investors may wish to consider to help them evaluate FBIO as an investment opportunity.

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement

MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional accredited investor. The Company issued 1,940,299 shares of common stock and pre-funded warran

Yahoo | January 31, 2023

Insiders own 28% of Fortress Biotech, Inc. (NASDAQ:FBIO) shares but individual investors control 41% of the company

To get a sense of who is truly in control of Fortress Biotech, Inc. ( NASDAQ:FBIO ), it is important to understand the...

Yahoo | January 28, 2023

Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

MIAMI, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,940,299 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offe

Yahoo | January 27, 2023

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another

Yahoo | January 20, 2023

Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference, taking place on Wednesday, January 18, 2023, at 11:00 a.m. EST. For more information and to register for the conference, please click here. A replay of the

Yahoo | January 17, 2023

Read More 'FBIO' Stories Here

FBIO Price Returns

1-mo 21.43%
3-mo 4.53%
6-mo -29.75%
1-year -55.50%
3-year -64.14%
5-year -76.12%
YTD 29.77%
2022 -73.80%
2021 -21.14%
2020 23.35%
2019 198.84%
2018 -78.45%

Continue Researching FBIO

Here are a few links from around the web to help you further your research on Fortress Biotech Inc's stock as an investment opportunity:

Fortress Biotech Inc (FBIO) Stock Price | Nasdaq
Fortress Biotech Inc (FBIO) Stock Quote, History and News - Yahoo Finance
Fortress Biotech Inc (FBIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9004 seconds.